DOD Breast Cancer Transformative Vision Award | Apply Online

Opportunity Summary:

The DOD Breast Cancer Transformative Vision Award (BCRP TVA) is a U.S. Department of Defense Breast Cancer Research Program funding opportunity designed for ambitious, high-impact research efforts that aim to change what is realistically possible in breast cancer prevention or treatment. Rather than supporting incremental advances, this award is intended for projects that articulate an extraordinary, bold vision and then back it up with a concrete, execution-ready strategy to move that vision toward real-world benefit for individuals who have breast cancer and/or those at risk for developing it. The program explicitly supports a wide range of research, from basic discovery through clinical studies, as long as the work is organized around a clear line of sight to meaningful patient impact.

A central requirement of the award is the "Vision and Impact" component. Applicants are expected to propose a fundamentally new approach that could be revolutionary in preventing breast cancer, treating it, or otherwise altering outcomes in a way that substantially advances the overarching goal of ending breast cancer. The opportunity recognizes that different projects may require different time horizons to reach a final endpoint, but it draws a firm line on significance: the anticipated outcome must be transformative. The application must clearly explain why the approach is not just novel but capable of reshaping current thinking or practice, and it must make a compelling case for how the proposed work would matter to people living with breast cancer and/or those at increased risk.

The second core requirement is "Implementation." The award is not simply looking for an inspiring idea; it demands a detailed plan that shows how the vision will be tested and advanced as quickly as possible. This includes identifying critical milestones, describing the innovations and technical solutions that will be used to hit those milestones, and laying out how the resulting advances will be translated to individuals with, and/or those at risk for, breast cancer. In practical terms, reviewers are looking for a project that reads like a carefully engineered roadmap: what will be built or proven, in what sequence, by whom, and how progress will be measured, managed, and adapted if challenges arise.

Team leadership and project management capacity are emphasized heavily. The Principal Investigator is expected to have demonstrated experience leading large, focused projects successfully, and to assemble the right team to match the scale and complexity of the proposed vision. The opportunity also places value on a research culture that actively supports innovation and creativity, with consistent and intensive interaction among team members. In other words, it is designed for coordinated, high-functioning teams where collaboration is not an afterthought but a central operating principle that keeps all contributors engaged across the full research plan.

From an administrative and funding standpoint, this opportunity was issued by the Department of the Army through the U.S. Army Medical Research Acquisition Activity (USAMRAA). It was posted on February 23, 2012, with an application deadline of August 15, 2012, and an archive date of September 14, 2012. The funding instrument types listed include cooperative agreement and grant, reflecting that awards may involve substantial programmatic involvement typical of cooperative agreements, depending on the final arrangement. The program anticipated making one award, with an estimated total funding amount of $3.9 million and no cost-sharing or matching requirement. Eligibility was listed as unrestricted, meaning it was broadly open to many entity types, subject to any additional eligibility details in the full announcement. The listing falls under CFDA 12.420 (Military Medical Research and Development), categorized within science and technology and other research and development activities.

For applicant support, the announcement directs anyone who has difficulty accessing the full opportunity announcement to contact the CDMRP Help Desk at 301-682-5507 or via email at help@cdmrp.org.

Browse more opportunities from the same agency: Dept. of the Army USAMRAA

Browse more opportunities from the same category: Science and Technology and other Research and Development

Next opportunity: DOD Breast Cancer Impact Award

Previous opportunity: DOD Breast Cancer Innovator Award

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for W81XWH 12 BCRP TVA

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (W81XWH 12 BCRP TVA) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 12 BCRP TVA", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.